Epigenetic drugs in cognitive disorders

Current Pharmaceutical Design

Volumn 20, Issue 11, 2014, Pages 1840-1846

  Peedicayil, Jacob ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Cognitive; DNA methylation; Epigenetic drug; Histone deacetylase

Indexed keywords

ANTAGOMIR; BUTYRIC ACID; DNA METHYLTRANSFERASE INHIBITOR; HISTONE ACETYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE INHIBITOR; METHYLTRANSFERASE INHIBITOR; S ADENOSYLMETHIONINE; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DNA METHYLATION; EPIGENETICS; GENE TARGETING; HUMAN; HUNTINGTON CHOREA; PARKINSON DISEASE; PRIORITY JOURNAL; ANIMAL; COGNITION DISORDERS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ANIMALS; COGNITION DISORDERS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84903702487     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990526     Document Type: Article

References (81)

1. Sadock BJ, Sadock VA. Kaplan & Sadock's synopsis of psychiatry. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins 2007.
2. Graff J, Mansuy IM. Epigenetic dysregulation in cognitive disorders. Eur J Neurosci 2009; 30: 1-8.
3. Fischer A, Sananbenesi F, Mungenast A, Tsai LH. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 2010; 31: 605-17.
4. Day JJ, Sweatt JD. Epigenetic mechanisms in cognition. Neuron 2011; 70: 813-29.
5. Gräff J, Tsai L-H. The potential of HDAC inhibitors as cognitive enhancers. Annu Rev Pharmacol Toxicol 2013; 53: 311-30.
6. Peedicayil J. Epigenetic therapy-A new development in pharmacology. Indian J Med Res 2006; 123: 17-24.
7. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol 2009; 49: 243-63.
8. Ropper AH, Samuels MA. Adams and Victor's principles of neurology. 9th ed. New York 2009.
9. Seeley WW, Miller BL. Dementia. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, Eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill 2012; pp. 3300-16.
10. Daniilidou M, Koutroumani M, Tsolaki M. Epigenetic mechanisms in Alzheimer's disease. Curr Med Chem 2011; 18: 1751-6.
11. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-83.
12. Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000; 7: 298-304.
13. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003; 348: 1365-75.
14. Vlaming H, van Leeuwen F. Crosstalk between aging and the epigenome. Epigenomics 2012; 4: 5-7.
15. Wang S-C, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset alzheimer's disease. PLoS One 2008; 7: e2698.
16. Ketelar ME, Hofstra RMW, Hayden MR. What monozygotic twins discordant for phenotype illustrate about mechanisms influencing genetic forms of neurodegeneration. Clin Genet 2012; 81: 325-33.
17. Ramos MI, Allen LH, Munges DM, et al. Low folate status is associated with impaired cognitive function and dementia in the Sacramento Area Latino Study on Aging. Am J Clin Nutr 2005; 82: 1346-52.
18. Oulhaj A, Refsum H, Munges DM, et al. Homocysteine as a predictor of cognitive decline in Alzheimer's disease. Int J Geriatr Psychiatry 2010; 25: 82-90.
19. Coppedè F. One-carbon metabolism and Alzheimer's disease: Focus on epigenetics. Curr Genet 2010; 11: 246-60.
20. Salbaum JM, Weidemann A, Lemmaire HG, Masters CL, Beyreuther K. The promoter of Alzheimer's disease amyloid A4 precursor gene. EMBO J 1988; 7: 2807-13.
21. Tohgi H, Utsugisawa A, Nagane Y, et al. Reduction with age in methylcytosine in the promoter region-224 approximately-101 of the amyloid precursor protein gene in autopsy human cortex. Brain Res Mol Brain Res 1999; 70: 288-92.
22. Babenko O, Kovalchuk I, Metz GA. Epigenetic programming of neurodegenerative diseases by an adverse environment. Brain Res 2012; 1444: 96-111.
23. Narayan P, Dragunow M. Pharmacology of epigenetics in brain disorders. Br J Pharmacol 2010; 159: 285-303.
24. Rao JS, Keleshian VL, Klein S, Rapoprt SI. Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients. Transl Psychiatry 2012; 2: e132.
25. Gräff J, Kim D, Dobbin MM, Tsai L-H. Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiol Rev 2011; 91: 603-49.
26. Day JJ, Sweatt JD. Epigenetic modifications in neurons are essential for formation and storage of behavioral memory. Neuropsychopharmacology 2011; 36: 357-8.
27. Peleg S, Sananbenesi F, Zovoilis A, et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 2010; 328: 753-6.
28. Govindrajan N, Agis-Balboa RC, Walter J, Sananbenesi F, Fischer A. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J Alzheimer's Dis 2011; 26: 187-97.
29. Cao X, Sudhof T. A trancriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001; 293: 115-20.
30. Lee J, Ryu H. Epigenetic modification is linked to Alzheimer's disease: Is it a maker or a marker? BMB Reports 2010; 43: 649-55.
31. Min S-W, Cho S-H, Zhou Y, et al. Acetylation of tau inhibits its degradation and contributes to taupathy. Neuron 2010; 67: 953-66.
32. Konecna A, Heraud JE, Schoderboeck L, Raposo AA, Kiebler MA. What are the roles of microRNAs at the mammalian synapse? Neurosci Lett 2009; 466: 63-8.
33. Hansen KF, Sakamoto K, Wayman GA, Impey S, Obrietan K. Transgenic mir132 alters neuronal spine density and impairs novel object recognition memory. PLoS One 2010; 5: e15497.
34. Zovoilis A, Agbemenyah HY, Agis -Balboa RC, et al. miR-32c is a novel target to treat dementias. EMBO J 2011; 30: 4299-308.
35. Mercer TR, Dinger ME, Mariani J, Kosik KS, Mehler MF, Mattick JS. Noncoding RNAs in long-term memory formation. Neuroscientist 2008; 14: 434-45.
36. Ridley RM, Frith CD, Crow TJ, Conneally PM. Anticipation in Huntington's disease is inherited through the male line but may originate in the female. J Med Genet 1988; 25: 589-95.
37. Farrer LA, Cupples LA, Kiely DK, Conneally PM, Myers RM. Inverse relationship between age of onset of Huntington's disease and paternal age. Am J Hum Genet 1992; 50: 528-35.
38. Gorbunova V, Seluanov A, Mittelman D, Wilson JH. Genomewide demethylation destabilizes CTG.CAG trinucleotide repeats in mammalian cells. Hum Mol Genet 2004; 13: 2979-89.
39. Debacker K, Frizzell A, Gleeson O, Kirkham-McCarthy L, Mertz T, Lahue RS. Histone deacetylase complexes promote trinucleotide repeat expansions. PLoS Biol 2012; 10: e1001257.
40. Gray SG. Targeting Huntington's disease through histone deacetylases. Clin Epigenetics 2011; 2: 257-77.
41. Coppedè F. Genetics and epigenetics of Parkinson's disease. Scientific World J 2012; 2012; 489830.
42. Kwok JBJ. Role of epigenetics in Alzheimer's and Parkinson's disease. Epigenomics 2010; 2: 671-82.
43. Heberlein I, Ludin H-P, Scholz J, Vieregg P. Personality, depression, and premorbid lifestyle in twin pairs discordant for Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 262-6.
44. Jowaed A, Schmitt I, Kaut O, Wüllner U. Methylation regulated alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci 2010; 30: 6355-9.
45. Su M, Shi JJ, Yang YP, et al. HDAC6 regulates aggresomeautophagy degradation pathway of α-synuclein in response to MPP+-induced stress. J Neurochem 2011; 117: 112-20.
46. Olzmann J, Li L, Chudaev MV, et al. Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. J Cell Biol 2007; 178: 1035-8.
47. Goers I, Manning-Bog AB, McCormack AL, et al. Nuclear localization of α-synuclein and its association with histones. Biochemistry 2003; 42: 8465-71.
48. Kontopoulos E, Parvin JD, Feany MB. α-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 2006; 15: 3012-3023.
49. Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010; 70: 7027-30.
50. Mai A. Small-molecule chromatin modifying agents: Therapeutic applications. Epigenomics 2010; 2: 307-24.
51. Scarpa S, Fuso A, D'Anselmi F, Cavallaro RA. Presenilin 1 gene silencing by S-adenosylmethionine: A treatment for Alzheimer's disease? FEBS Lett 2003; 541: 145-8.
52. Fuso A, Nicolia V, Ricceria L, et al. S-adenosylmethionine reduces the progress of the Alzheimers' disease like features induced by Bvitamin deficiency in mice. Neurobiol Aging 2012; 33: e1-e16.
53. Cavallaro RA, Fuso A, Nicolia V, Scarpa S. S-adenosylmethionine prevents oxidative stress and modulated glutathione metabolism in TgCRND8 mice fed a B-vitamin deficient diet. J Alzheimer's Dis 2010; 20: 997-1002.
54. Chan A, Shea TB. Folate deprivation increases presenilin expression, gamma secretase activity, and Abeta levels in murine brain: Potentiation by ApoE deficiency and alleviation by dietary Sadenosylmethionine. J Neurochem 2007; 102: 753-60.
55. Chan A, Shea TB. Supplementation with apple juice attenuates presenilin-1 overexpression during dieting and genetically-induced oxidative stress. J Alzheimer's Dis 2006; 10: 353-8.
56. Chan A, Rogers E, Shea TB. Dietary deficiency in folate and vitamin E under conditions of oxidative stress increase phospo-tau levels: Potentiation by ApoE4 and alleviation by Sadenosylmethionine. J Alzheimer's Dis 2009; 17: 483-7.
57. Chan A, Remington R, Kotyla E, Lepore A, Zemianek J, Shea TB. A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia. J Nutr Health Aging 2010; 14: 224-30.
58. Nuutinen T, Suuronen T, Kaupinen A, Salminen A. Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's disease. Neurosci Lett 2010; 475: 64-8.
59. Kilgore M, Miller CA, Fass DM, et al. Inhibitors of class 1 deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010; 35: 870-80.
60. Naliveava N, Belyaev ND, Lewis DI., et al. Effect of sodium valproate administration on brain neprilysin expreesion and memory in rats. J Mol Neurosci 2012; 46: 569-77.
61. Drzewinska J, Walczak-Drzewieka A, Ratejewsky M. Identification and analysis of the promoter region of the human DCHR24 gene: Involvement of DNA methylation and histone acetylation. Mol Biol Rep 2011; 38: 1091-101.
62. Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003; 100: 2041-6.
63. Mielcarek M, Benn CL, Franklin SA, et al. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. PLoS One 2011; 6: e27746.
64. Thomas EA, Coppola G, Desplats PA, et al. The HDAC inhibitor 4b ameliorates the disease phenotype in and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci USA 2008; 105: 15564-9.
65. Ebbel EN, Leymarie N, Schiavo S, et al. Identification of phenylbutyrate-generated Metabolites in Huntington's disease patients using parallel liquid chromatography/ electrochemical array/mass spectrometry and off-line tandem mass spectrometry. Anal Biochem 2010; 399: 152-61.
66. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophilia. Nature 2001; 413: 739-43.
67. Sadri-Vakili G, Bouzou B, Benn CL, et al. Histones associated with downregulated genes are hypoacetylated in Huntington's disease models. Hum Mol Genet 2007; 16: 1293-306.
68. Chen SH, Wu HM, Ossola B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. Br J Pharmacol 2012; 165: 494-505.
69. Gardian G, Yang L, Cleren C, Calingasan NY, Kivenyi P, Beal MF. Neuroprotective effects of phenylbutyrate against MPTP toxicity. Neuromolecular Med 2004; 5: 325-41.
70. Kidd SK, Schneider JS. Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 2011; 194: 189-94.
71. Chen PS, Peng GS, Li G. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006; 11: 1116-25.
72. Wu X, Chen PS, Dallas S, et al. Histone deacetylase inhibitors upregulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol 2008; 11: 1123-34.
73. Chen PS, Wang CC, Bortner CD, et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced neurotoxicity. Neuroscience 2007; 149: 203-12.
74. Huang HY, Lin SZ, Chen WF, Li KW, Kuo JS, Wang MJ. Urocortin modulates dopaminergic neuronal survival via inhibition of glycogen synthase kinase-3ß and histone deacetylase. Neurobiol Aging 2011; 32: 1662-77.
75. Rößler R, Boddek E, Copray S. Differentiation of nonmesencephalic neural stem cells towards dopaminergic neurons. Neuroscience 2010; 170: 417-28.
76. Gupta S, Kim SY, Artis S, et al. Histone methylation regulates memory formation. J Neurosci 2010; 30: 3589-99.
77. Guan J-S, Haggarty SJ, Giacometti E, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009; 459: 55-60.
78. Graff J, Rei D, Guan S, et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012; 483: 222-6.
79. Peedicayil J. Epigenetic management of major psychosis. Clin Epigenetics 2011; 2: 249-56.
80. Boks MP, de jong NM, Kas MJ, et al. Current status and future prospects for epigenetic psychopharmacology. Epigenetics 2012; 7: 1
81. Peedicayil J. Epigenetic biomarkers in psychiatric disorders. Br J Pharmacol 2008; 155: 795-6.